# Metastatic mediastinal malignant tumors of gastrointestinal origin with occult primary lesions: a case report

**Authors:** Yaxuan Liu, Liang liang Yang, Wen teng Hu, Rui jiang Lin, Song la Bai, Min jie Ma, Biao Han

PMC · DOI: 10.3389/fonc.2025.1625668 · 2025-07-09

## TL;DR

A rare case of metastatic gastrointestinal cancer in the chest area with no identifiable primary tumor is reported, highlighting diagnostic challenges and the need for advanced testing.

## Contribution

This case report highlights the diagnostic challenges of GI-origin mediastinal CUP and emphasizes the need for molecular profiling and advanced diagnostics.

## Key findings

- A mediastinal mass with GI immunohistochemical features was found in a patient with no identifiable primary tumor.
- Conventional imaging failed to detect the primary lesion despite comprehensive evaluations.
- Molecular profiling and ctDNA analysis are suggested for accurate diagnosis and treatment planning.

## Abstract

Cancer of unknown primary origin (CUP), accounting for 3–5% of malignancies, poses significant diagnostic challenges because of the absence of identifiable primary lesions. While common occult primary tumors involve the lung or pancreas, gastrointestinal (GI)-originated mediastinal metastases are exceedingly rare. A 54-year-old male presented with chest tightness and dyspnea. Imaging revealed a 45.5 × 36.3 mm anterior mediastinal mass. Pathological evaluation postresection revealed metastatic moderately differentiated adenocarcinoma with immunohistochemical (IHC) features (CK20+/Villin+/CK7−/TTF-1−) suggestive of GI origin. Despite comprehensive evaluations (gastroscopy, PET-CT), no primary lesions were detected. Chronic atrophic gastritis (C2) was noted, but malignancy was excluded. This case underscores the diagnostic complexity of GI-profile mediastinal CUP and highlights limitations in conventional imaging. Molecular profiling (e.g., KRAS/NRAS/BRAF mutation) and advanced diagnostics (ctDNA analysis) are critical for accurate classification and tailored therapy. Long-term surveillance remains essential, as 12% of CUPs reveal primaries during follow-up.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]
- **Diseases:** chronic atrophic gastritis (MONDO:0006665)

## Full-text entities

- **Genes:** KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}
- **Diseases:** mediastinal malignant tumors (MESH:D008479), CUP (MESH:D009369), Chronic atrophic gastritis (MESH:D005757), adenocarcinoma (MESH:D000230), metastases (MESH:D009362), mediastinal (MESH:D008480), dyspnea (MESH:D004417), CUPs (MESH:C536557), chest tightness (MESH:D002637)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12284500/full.md

---
Source: https://tomesphere.com/paper/PMC12284500